Ji Eun Jun1, Tae Hyuk Kim2, Seung-Eun Lee1, You-Bin Lee1, Jae Hwan Jee3, Ji Cheol Bae4, Sang-Man Jin1, Kyu Yeon Hur1, Jae Hyeon Kim1, Sun Wook Kim1, Jae Hoon Chung1, Yong-Ki Min1, Moon-Kyu Lee1. 1. Division of Endocrinology and Metabolism, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, Korea. 2. Division of Endocrinology and Metabolism, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, Korea. taehyukmd.kim@samsung.com. 3. Department of Health Promotion, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. 4. Division of Endocrinology and Metabolism, Department of Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, South Korea.
Abstract
PURPOSE: Metabolically healthy obese is the designation for a subgroup of obese individuals with normal metabolic features. However, metabolically healthy obese individuals are prone to developing metabolic syndrome. Serum triiodothyronine (T3) levels are associated with various metabolic risk factors including obesity. Therefore, this longitudinal study aimed to explore the possible correlation between serum T3 concentration and the onset of MetS in metabolically healthy obese persons. METHODS: A retrospective analysis of 992 euthyroid metabolically healthy obese subjects who underwent yearly health checkups over 6 years was performed. The risk of developing MetS was analyzed according to baseline T3 concentration, as both tertiles and continuous values, using Cox regression analysis. Serum T3 concentration at the end of the study was further analyzed according to the final metabolic phenotype. RESULTS: The incidence of MetS was 464 cases (46.8%) during a median 3.3 years of follow-up (3168.2 person-years). The hazard ratio for incident MetS enhanced with increasing T3 concentration in both the crude and adjusted models. Higher baseline serum T3 levels were associated with unfavorable metabolic parameters. However, over the course of the study, serum T3 concentration significantly increased in subjects who sustained metabolically healthy phenotypes compared to baseline value, while it significantly decreased in the subjects who developed MetS. CONCLUSIONS: Serum T3 concentrations exhibit distinct associations with development of metabolic syndrome in euthyroid metabolically healthy obese persons, but its increment during follow-up maintained metabolically healthy state. These findings suggest that serum T3 modulation might be an adaptive process to protect against metabolic deterioration.
PURPOSE: Metabolically healthy obese is the designation for a subgroup of obese individuals with normal metabolic features. However, metabolically healthy obese individuals are prone to developing metabolic syndrome. Serum triiodothyronine (T3) levels are associated with various metabolic risk factors including obesity. Therefore, this longitudinal study aimed to explore the possible correlation between serum T3 concentration and the onset of MetS in metabolically healthy obesepersons. METHODS: A retrospective analysis of 992 euthyroid metabolically healthy obese subjects who underwent yearly health checkups over 6 years was performed. The risk of developing MetS was analyzed according to baseline T3 concentration, as both tertiles and continuous values, using Cox regression analysis. Serum T3 concentration at the end of the study was further analyzed according to the final metabolic phenotype. RESULTS: The incidence of MetS was 464 cases (46.8%) during a median 3.3 years of follow-up (3168.2 person-years). The hazard ratio for incident MetS enhanced with increasing T3 concentration in both the crude and adjusted models. Higher baseline serum T3 levels were associated with unfavorable metabolic parameters. However, over the course of the study, serum T3 concentration significantly increased in subjects who sustained metabolically healthy phenotypes compared to baseline value, while it significantly decreased in the subjects who developed MetS. CONCLUSIONS: Serum T3 concentrations exhibit distinct associations with development of metabolic syndrome in euthyroid metabolically healthy obesepersons, but its increment during follow-up maintained metabolically healthy state. These findings suggest that serum T3 modulation might be an adaptive process to protect against metabolic deterioration.
Authors: Vicente A Benites-Zapata; Diego Urrunaga-Pastor; Cristina Torres-Mallma; Christian Prado-Bravo; Mirella Guarnizo-Poma; Herbert Lázaro-Alcántara Journal: Diabetes Metab Syndr Date: 2017-04-28
Authors: Rachel P Wildman; Robert Kaplan; JoAnn E Manson; Aleksandar Rajkovic; Stephanie A Connelly; Rachel H Mackey; Lesley F Tinker; J David Curb; Charles B Eaton; Sylvia Wassertheil-Smoller Journal: Obesity (Silver Spring) Date: 2011-01-13 Impact factor: 5.002
Authors: Jose de Jesus Garduño-Garcia; Ulices Alvirde-Garcia; Guadalupe López-Carrasco; Ma Elena Padilla Mendoza; Roopa Mehta; Olimpia Arellano-Campos; Ricardo Choza; Leobardo Sauque; Maria Eugenia Garay-Sevilla; Juan Manuel Malacara; Francisco J Gomez-Perez; Carlos A Aguilar-Salinas Journal: Eur J Endocrinol Date: 2010-06-01 Impact factor: 6.664
Authors: Brian Finan; Christoffer Clemmensen; Zhimeng Zhu; Kerstin Stemmer; Karine Gauthier; Luisa Müller; Meri De Angelis; Kristin Moreth; Frauke Neff; Diego Perez-Tilve; Katrin Fischer; Dominik Lutter; Miguel A Sánchez-Garrido; Peng Liu; Jan Tuckermann; Mohsen Malehmir; Marc E Healy; Achim Weber; Mathias Heikenwalder; Martin Jastroch; Maximilian Kleinert; Sigrid Jall; Sara Brandt; Frédéric Flamant; Karl-Werner Schramm; Heike Biebermann; Yvonne Döring; Christian Weber; Kirk M Habegger; Michaela Keuper; Vasily Gelfanov; Fa Liu; Josef Köhrle; Jan Rozman; Helmut Fuchs; Valerie Gailus-Durner; Martin Hrabě de Angelis; Susanna M Hofmann; Bin Yang; Matthias H Tschöp; Richard DiMarchi; Timo D Müller Journal: Cell Date: 2016-10-06 Impact factor: 41.582
Authors: Galina Bryzgalova; Suad Effendic; Akhtar Khan; Stefan Rehnmark; Peter Barbounis; Jamie Boulet; Gao Dong; Rajni Singh; Sue Shapses; Johan Malm; Paul Webb; John D Baxter; Gary J Grover Journal: J Steroid Biochem Mol Biol Date: 2008-06-22 Impact factor: 4.292